Avadel Pharmaceuticals plc (NASDAQ: AVDL)’s stock price has plunge by 2.00relation to previous closing price of 11.00. Nevertheless, the company has seen a 5.75% surge in its stock price over the last five trading sessions. globenewswire.com reported 2025-01-03 that DUBLIN, Jan. 03, 2025 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, January 8, 2025, to provide a corporate update and discuss the Company’s preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2024.
Is It Worth Investing in Avadel Pharmaceuticals plc (NASDAQ: AVDL) Right Now?
Company’s 36-month beta value is 1.30.Analysts have differing opinions on the stock, with 7 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AVDL is 88.15M, and currently, short sellers hold a 13.08% ratio of that floaft. The average trading volume of AVDL on January 03, 2025 was 1.17M shares.
AVDL’s Market Performance
AVDL stock saw an increase of 5.75% in the past week, with a monthly gain of 12.88% and a quarterly increase of -12.41%. The volatility ratio for the week is 4.06%, and the volatility levels for the last 30 days are 5.24% for Avadel Pharmaceuticals plc (AVDL). The simple moving average for the past 20 days is 7.59% for AVDL’s stock, with a -23.11% simple moving average for the past 200 days.
Analysts’ Opinion of AVDL
Many brokerage firms have already submitted their reports for AVDL stocks, with Rodman & Renshaw repeating the rating for AVDL by listing it as a “Buy.” The predicted price for AVDL in the upcoming period, according to Rodman & Renshaw is $27 based on the research report published on June 12, 2024 of the previous year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see AVDL reach a price target of $29, previously predicting the price at $27. The rating they have provided for AVDL stocks is “Outperform” according to the report published on March 05th, 2024.
Needham gave a rating of “Buy” to AVDL, setting the target price at $22 in the report published on March 05th of the previous year.
AVDL Trading at -4.77% from the 50-Day Moving Average
After a stumble in the market that brought AVDL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.23% of loss for the given period.
Volatility was left at 5.24%, however, over the last 30 days, the volatility rate increased by 4.06%, as shares surge +13.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.69% lower at present.
During the last 5 trading sessions, AVDL rose by +6.13%, which changed the moving average for the period of 200-days by -28.73% in comparison to the 20-day moving average, which settled at $10.43. In addition, Avadel Pharmaceuticals plc saw 6.76% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AVDL starting from MCHUGH THOMAS S, who purchase 2,300 shares at the price of $10.44 back on Dec 13 ’24. After this action, MCHUGH THOMAS S now owns 87,800 shares of Avadel Pharmaceuticals plc, valued at $24,019 using the latest closing price.
MCHUGH THOMAS S, the Chief Financial Officer of Avadel Pharmaceuticals plc, purchase 5,000 shares at $10.49 during a trade that took place back on Dec 11 ’24, which means that MCHUGH THOMAS S is holding 85,500 shares at $52,432 based on the most recent closing price.
Stock Fundamentals for AVDL
Current profitability levels for the company are sitting at:
- -0.46 for the present operating margin
- 0.92 for the gross margin
The net margin for Avadel Pharmaceuticals plc stands at -0.53. The total capital return value is set at -0.55. Equity return is now at value -78.54, with -40.17 for asset returns.
Currently, EBITDA for the company is -149.12 million with net debt to EBITDA at 0.44. When we switch over and look at the enterprise to sales, we see a ratio of 7.6. The receivables turnover for the company is 3.72for trailing twelve months and the total asset turnover is 0.87. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.97.
Conclusion
In a nutshell, Avadel Pharmaceuticals plc (AVDL) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
